Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
<p>Abstract</p> <p>Background</p> <p>Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and i...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-02-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | http://www.cancerci.com/content/12/1/5 |
id |
doaj-5e000797eb4c4f08ac8cc3c1f7ebdc1c |
---|---|
record_format |
Article |
spelling |
doaj-5e000797eb4c4f08ac8cc3c1f7ebdc1c2020-11-25T00:55:04ZengBMCCancer Cell International1475-28672012-02-01121510.1186/1475-2867-12-5Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo modelsHijona ElizabethBanales JesúsHijona LanderMedina JuanArenas JuanHerreros-Villanueva MartaAldazabal PabloBujanda Luis<p>Abstract</p> <p>Background</p> <p>Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models.</p> <p>Method</p> <p>We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels.</p> <p>Results</p> <p>We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L).</p> <p>Conclusion</p> <p>The combination of pravastatin + sorafenib were more effective than Sorafenib alone.</p> http://www.cancerci.com/content/12/1/5PravastatinSorafenibHepatocarcinomaStatins |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hijona Elizabeth Banales Jesús Hijona Lander Medina Juan Arenas Juan Herreros-Villanueva Marta Aldazabal Pablo Bujanda Luis |
spellingShingle |
Hijona Elizabeth Banales Jesús Hijona Lander Medina Juan Arenas Juan Herreros-Villanueva Marta Aldazabal Pablo Bujanda Luis Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models Cancer Cell International Pravastatin Sorafenib Hepatocarcinoma Statins |
author_facet |
Hijona Elizabeth Banales Jesús Hijona Lander Medina Juan Arenas Juan Herreros-Villanueva Marta Aldazabal Pablo Bujanda Luis |
author_sort |
Hijona Elizabeth |
title |
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models |
title_short |
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models |
title_full |
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models |
title_fullStr |
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models |
title_full_unstemmed |
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models |
title_sort |
pravastatin inhibits cell proliferation and increased mat1a expression in hepatocarcinoma cells and in vivo models |
publisher |
BMC |
series |
Cancer Cell International |
issn |
1475-2867 |
publishDate |
2012-02-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models.</p> <p>Method</p> <p>We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels.</p> <p>Results</p> <p>We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L).</p> <p>Conclusion</p> <p>The combination of pravastatin + sorafenib were more effective than Sorafenib alone.</p> |
topic |
Pravastatin Sorafenib Hepatocarcinoma Statins |
url |
http://www.cancerci.com/content/12/1/5 |
work_keys_str_mv |
AT hijonaelizabeth pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels AT banalesjesus pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels AT hijonalander pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels AT medinajuan pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels AT arenasjuan pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels AT herrerosvillanuevamarta pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels AT aldazabalpablo pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels AT bujandaluis pravastatininhibitscellproliferationandincreasedmat1aexpressioninhepatocarcinomacellsandinvivomodels |
_version_ |
1725232283700428800 |